4basebio PLC
4BB.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 84.4% | 88.8% | -20.7% | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 67.5% | 67.2% | 89.2% | 79.6% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £0 | £0 | £0 | £0 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -1,290.7% | -1,591.3% | -2,179.1% | -1,043.5% |
| Other Income/Exp. Net | -£0 | -£0 | -£0 | -£0 |
| Pre-Tax Income | -£0 | -£0 | -£0 | -£0 |
| Tax Expense | -£0 | -£0 | -£0 | -£0 |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -1,321.9% | -1,514.8% | -1,921.6% | -957.1% |
| EPS | -0.94 | -0.62 | -0.42 | -0.26 |
| % Growth | -51.6% | -47.6% | -61.5% | – |
| EPS Diluted | -0.94 | -0.62 | -0.42 | -0.26 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | -1,175.7% | -1,451.2% | -2,018.3% | -948.8% |